Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
1.460
0.00 (0.00%)
At close: Jun 13, 2025, 4:00 PM
1.520
+0.060 (4.11%)
After-hours: Jun 13, 2025, 7:56 PM EDT
Prime Medicine Revenue
Prime Medicine had revenue of $1.45M in the quarter ending March 31, 2025, with 146.02% growth. This brings the company's revenue in the last twelve months to $3.85M, up 550.76% year-over-year. In the year 2024, Prime Medicine had annual revenue of $2.98M.
Revenue (ttm)
$3.85M
Revenue Growth
+550.76%
P/S Ratio
47.53
Revenue / Employee
$17,972
Employees
214
Market Cap
186.62M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PRME News
- 16 days ago - Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 26 days ago - Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition - GlobeNewsWire
- 26 days ago - Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease - GlobeNewsWire
- 5 weeks ago - Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 3 months ago - Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 4 months ago - Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm - PRNewsWire